- Home
- AMTM vs CYTK Comparison
AMTM vs CYTK Comparison
Compare AMTM & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTM
- CYTK
- Stock Information
- Founded
- AMTM 2020
- CYTK 1997
- Country
- AMTM United States
- CYTK United States
- Employees
- AMTM N/A
- CYTK N/A
- Industry
- AMTM
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- AMTM
- CYTK Health Care
- Exchange
- AMTM NYSE
- CYTK Nasdaq
- Market Cap
- AMTM 5.1B
- CYTK 5.6B
- IPO Year
- AMTM N/A
- CYTK 2004
- Fundamental
- Price
- AMTM $17.38
- CYTK $37.37
- Analyst Decision
- AMTM Buy
- CYTK Strong Buy
- Analyst Count
- AMTM 4
- CYTK 17
- Target Price
- AMTM $26.50
- CYTK $82.00
- AVG Volume (30 Days)
- AMTM 3.3M
- CYTK 1.9M
- Earning Date
- AMTM 05-06-2025
- CYTK 05-07-2025
- Dividend Yield
- AMTM N/A
- CYTK N/A
- EPS Growth
- AMTM N/A
- CYTK N/A
- EPS
- AMTM N/A
- CYTK N/A
- Revenue
- AMTM $9,821,000,000.00
- CYTK $18,474,000.00
- Revenue This Year
- AMTM $70.72
- CYTK $55.82
- Revenue Next Year
- AMTM $0.05
- CYTK $683.10
- P/E Ratio
- AMTM N/A
- CYTK N/A
- Revenue Growth
- AMTM 22.69
- CYTK 145.34
- 52 Week Low
- AMTM $16.95
- CYTK $37.46
- 52 Week High
- AMTM $34.50
- CYTK $75.71
- Technical
- Relative Strength Index (RSI)
- AMTM N/A
- CYTK 38.67
- Support Level
- AMTM N/A
- CYTK $37.46
- Resistance Level
- AMTM N/A
- CYTK $43.69
- Average True Range (ATR)
- AMTM 0.00
- CYTK 2.44
- MACD
- AMTM 0.00
- CYTK -0.41
- Stochastic Oscillator
- AMTM 0.00
- CYTK 17.68
About AMTM AMENTUM HOLDINGS INC
Amentum Holdings Inc is engaged in engineering and technology solutions. The United States and its allies trust it to address their technical and complex scientific, security, and sustainability challenges.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.